Useful Links
Adult BNF Paediatric BNFBNF Apps (iOS and Android)
Further Medicines Management Resources
Antimicrobial guidelines
MHRA: Drug Safety Update (June 2019) Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
MHRA: Drug Safety Update (June 2019) Lartruvo▼ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy
MHRA: Drug Safety Update (June 2019) GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
MHRA: Drug Safety Update (June 2019) Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome
MHRA: Drug Safety Update (May 19) Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy
MHRA: Drug Safety Update (May 19) Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
